THE CD-1 MICE MYOCARDIUM AND LIVER MORPHOLOGICAL REACTIONS AT THE TREATMENT BY DIFFERENT DOSES OF BORPHENYLALANINE

The potential of Boron-neutron capture therapy is driven by its effectiveness for radio-resistant and other types of tumors that are tough to treat with conventional treatments or if they are not available. In order to improve the effectiveness of therapy, the dose of the substance needs to increase, which raises the question of its effect on conventionally healthy tissues. The study is to evaluate the dynamic changes in myocardium and liver in mice caused by a single injection of L-p-boron-phenylalanine, whether it is a therapeutic or sub-lethal dose. The light-optical and polarization microscopic examination of the myocardium and liver of the male mice of the CD-1 (n=54) line was carried out after the injection of the Boron-containing substance (in doses of 700 and 3000 mg/kg; once intraperitoneal) used in clinical Boron-neutron treatment. Evaluation of structural changes in the myocardium and liver was done 1, 3, and 7 days after injection. Cardiomyocytes are susceptible to lytic and contracture damage caused by high doses of the substance. Moderate blood-fullness was observed throughout the study as evidence of hemodynamic impairments. Mononuclear cells infiltrating the liver for 3 days resulted in mono-cellular necrosis, which persisted until the end of the experiment regardless of the dose. Paracentral hepatocytes have been often dystrophic. Regardless of the dose after 1 or 7 days, the number of bi-nuclear hepatocytes was 14-16% higher than the number of control group animals, while for 3 days there was a reliable transient decrease in the number of bi-nuclear hepatocytes both compared to the control group animals and data in other periods of the experiment. The most significant differences were observed in the animal group with the injection of a lower dose. The obtained data show that the used doses of L-p-boron-phenylalanine with a single injection cause non-specific structural changes of the myocardium and liver of varying severity, characterized by dose and time-dependent effects and require study in later periods after substance injection.

1. Pozzi ECC, Cardoso JE, Colombo LL et al. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model. Radiat Environ Biophys. 2012;51:331-339. DOI: 10.1007/s00411-012-0419-8

2. Yoshimoto M, Kurihara H, Honda N et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-18F-fluoro-phenylalanine uptake in human glioblastoma cells. Nuclear Medicine and Biology. 2013;40(5):625-629. DOI: 10.1016/j.nucmedbio.2013.02.010

3. Estrella V, Chen T, Lloyd M et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524-1535. DOI: 10.1158/0008-5472.CAN-12-2796

4. Wittig A., Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 2000;153(2):173-180. DOI: 10.1667/0033-7587

5. Kanygin VV, Kichigin AI, Zavyalov EL et al. Radiobiologicheskie effekty puchka uskoritel’nogo istochnika neytronov v institute yadernoy fiziki im. G.I. Budkera SO RAN. Sovremennye problemy nauki i obrazovaniya. 2019;6:183. In Russian

6. Sauerwein W. Neutron Capture Therapy. Principles and Applications. London: Springer, 2012.- 553pp. DOI:10.1007/978-3-642-31334-9

7. Matsumura A, Asano T, Hirose K et al. Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan. Cancer Biother Radiopharm. 2023;38(3):201-207. DOI: 10.1089/cbr.2022.0056

8. Suzuki M, Masunaga S-I, Kinashi Y et al. The Effects of Boron Neutron Capture Therapy on Liver Tumors and Normal Hepatocytes in Mice. Jpn J Cancer Res. 2000;91:1058–1064

9. Kanygin VV, Kasatova AI, Razumrv IA i dr. Otsenka effektivnosti bor-neytronzakhvatnoy terapii na razlichnye opukholevye i normal'nuyu kletoch-nuyu strukturu. Sibirsky onkologichesky zhurnal. 2021;20(3):56-66. In Russian

10. Chou FI, Chung HP, Liu HM et al. Suitability of boron carriers for BNCT: Accumulation of boron in malignant and normal liver cells after treat-ment with BPA, BSH and BA. Applied Radiation and Isotopes. 2009;67:105-108

11. Taniyama K, Fujiwara H, Kuno T et al. Acute and subacute toxicity of 10 B-paraboronophenylalanine. Pigment Cell Res. 1989;2:291-296. DOI: 10.1111/j.1600-0749.1989.tb00207.x

12. Kulvik M, Vähätalo J, Buchar E et al. Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway. Eur J Pharm Sci. 2003;18(2):155-163. DOI: 10.1016/s0928-0987(02)00256-7

13. Emiliano CC, Pozzi JE, Cardoso LL et al. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model. Radiat Environ Biophys. 2012;51:331-339

14. Trivillin VA, Pozzi ECC, Colombo LL et al. Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer. Radiat Environ Biophys. 2017;56:365-375

15. Advances in Boron Neutron Capture Therapy, International atomic energy agency, Non-serial Publications IAEA. IAEA: Vienna, 2023.- 416pp. URL: https://www-pub.iaea.org/MTCD/Publications/PDF/CRCP-BOR-002_web.pdf Date 20.06.2024

16. Carpano M, Perona M, Rodriguez C et al. Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment. International Journal of Radiation Oncology, Biology, Physics. 2015;93(2):344-352. DOI:10.1016/j.ijrobp.2015.05.039

17. Fukuda H. Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results. Cells. 2021;10:2881. DOI:10.3390/cells10112881

18. Coderre JA, Button TM, Micca PL et al. Neutron capture therapy of the 9l rat gliosarcoma using the P-boronophenylalanine-fructose complex. Inter-national Journal of Radiation Oncology, Biology, Physics. 1994;30(3):643-652. DOI:10.1016/0360-3016(92)90951-D

19. Carpano M, Perona M, Rodriguez C et al. Experimental Studies of Boronophenylalanine (10BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment. International Journal of Radiation Oncology, Biology, Physics. 2015;93(2):344-352. DOI:10.1016/j.ijrobp.2015.05.039

20. Fukuda H. Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results. Cells. 2021;10:2881. DOI:10.3390/cells101128

21. Coderre JA, Joel DD, Micca PL et al. Control of Intracerebral Gliosarcomas in Rats by Boron Neutron Capture Therapy with p-Boronophenylalanine. Radiation Research. 1992;129(3):290-296. DOI:10.2307/3578028

22. Coderre JA, Joel DD, Micca PL et al. Control of Intracerebral Gliosarcomas in Rats by Boron Neutron Capture Therapy with p-Boronophenylalanine. Radiation Research. 1992;129(3):290-296. DOI:10.2307/3578028

23. Mallesch JL, Moore DE, Allen BJ et al. The pharmacokinetics of p-boronophenylalanine fructose in human patients with glioma and metastatic mela-noma. Int J Radiat Oncol Biol Phys. 1994;28(5):1183-1188. DOI:10.1016/0360-3016(94)90493-6

24. Sun T, Zhou Y, Xie X et al. Selective uptake of boronophenylalanine by glioma stem/progenitor cells. Applied Radiation and Isotopes. 2012;70(8):1512-1518. DOI:10.1016/j.apradiso.2012.04.005

25. Coderre JA, Chanana AD, Joel DD et al. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiat Res. 1998;149(2):163-170

26. Coderre JA, Elowitz EH, Chadha M. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neu-trons: Trial design and early clinical results. J Neurooncol. 1997;33:141-152. DOI:10.1023/A:1005741919442

27. Gimatdinova GR, Danilova OE, Davydkin IL i dr. Sovremennye aspekty ranney diagnostiki kardiotoksicheskikh oslozhneny lekarstvennoy terapii v onkologii (obzor literatury). Klinicheskaya onkogematologiya. 2022;15(1):107-113. In Russian

28. Vatutin NT, Sklyannaya EV, Jel'-Hatib MA i dr. Gepatotoksichnost' protivoopukholevykh preparatov: sovremennoe sostoyanie problem. Rossiysky onkologichesky zhurnal. 2016;21(6):325-333. In Russian

29. Sauerwein WAG, Bet PM, Wittig A. Drugs for BNCT: BSH and BPA. Berlin, Heidelberg: Springer, 2012.- 44pp

30. Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018;38(1):35

31. Kanygin VV, Kichigin AI, Krivoshapkin AL, Taskaev SYu. Perspectives of Boron-Neutron Capture Therapy of Malignant Brain Tumors. Physics of Cancer: Interdisciplinary Problems and Clinical Applications. AIP Conf. Proc. 2017;1882:020030. DOI: 020030-1–020030-10

32. Kanygin VV, Koldysheva EV, Zav’yalov EL i dr. Strukturnye reaktsii serdtsa i pecheni myshey CD-1 na odnokratnoe vvedenie borkaptata natriya. Morfologicheskie vedomosti. 2023;31(3):30-37. In Russian. DOI: 10.20340/mv-mn.2023.31(3).812